Identification of anticancer drugs associated to cancer therapy-related cardiac dysfunction: a VigiBase® disproportionality analysis
This disproportionality study identified 25 anticancer drugs significantly associated with CTRCD reporting, including new signals. It highlights discrepancies compared with drugs recommended for cardiac dysfunction evaluation in the 2022 ESC Guidelines. This underscores the importance of including CTRCD as a safety endpoint in cancer studies.
Authors
- Jonaz Font (ORCID: https://orcid.org/0000-0002-3103-9739)
- Angélique Da Silva (ORCID: https://orcid.org/0000-0002-8193-5144)
- Paul Milliez (ORCID: https://orcid.org/0000-0003-4820-5585)
- Damien Legallois (ORCID: https://orcid.org/0000-0002-2297-4418)
- Basile ChréTien
- Katrien Blanchart (ORCID: https://orcid.org/0000-0002-5849-0917)
- Rémi Sabatier
- Charles Dolladille (ORCID: https://orcid.org/0000-0003-0449-6261)
- Anne‐Flore Plane (ORCID: https://orcid.org/0000-0002-6676-085X)
- Joachim Alexandre (ORCID: https://orcid.org/0000-0002-9197-8404)
Institutions
- Inserm (FR)
- Nagoya University Hospital (JP)
- Normandie Université (FR)
- Cyceron (FR)
- Université de Caen Normandie (FR)
Publication Details
- Journal
- European Heart Journal - Cardiovascular Pharmacotherapy
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1093/ehjcvp/pvaf027
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00